Description: Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics. The company operates in four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience division manufactures and sells plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, such as analytical instruments and reagents for diagnostics, as well as blood bank products. This division serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital division manufactures and installs products used by and in hospitals comprising parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others division engages in the sale of intermediate pastes and plasma to third parties. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. The company was formerly known as Probitas Pharma, S.A. and changed its name to Grifols, S.A. in 2005. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Home Page: www.grifols.com
GRFS Technical Analysis
Avinguda de la Generalitat, 152
Barcelona,
08174
Spain
Phone:
34 93 571 02 21
Officers
Name | Title |
---|---|
Mr. Steven Francis Mayer J.D. | Exec. Chairman |
Mr. Raimon Grifols Roura | Co-CEO & Exec. Director |
Mr. Víctor Grifols Deu | Co-CEO & Exec. Director |
Mr. Alfredo Arroyo Guerra | CFO & VP |
Mrs. Eva Bastida Tubau | Corp. VP and Director of Scientific & Medical Affairs |
Ms. Nuria Pascual Lapeña | VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer |
Mr. David Ian Bell | Gen. Counsel & Chief Corp. Devel. Officer |
Mr. Mateo Florencio Borrás Humbert | Corp. VP & Chief HR Officer |
Ms. Maria Teresa-Rioné Llano | Chief Communications Officer |
Ms. Montserrat Gaja Llamas | Chief HR Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 13.2802 |
---|---|
Trailing PE: | 88.5 |
Price-to-Book MRQ: | 0.7986 |
Price-to-Sales TTM: | 1.2683 |
IPO Date: | 2006-05-17 |
Fiscal Year End: | December |
Full Time Employees: | 27584 |